Device Authority expands enterprise reach through IoT security partnership

Tern plc

Device Authority has strengthened its enterprise positioning through a strategic partnership with Xalient, a provider of identity-led cybersecurity services and managed solutions. The collaboration will see Xalient integrate Device Authority’s KeyScaler platform into its IoT security offering, with the aim of helping enterprise customers protect connected devices across complex IT, IoT and operational technology environments.

This places Device Authority’s technology within a managed security model that is designed for large organisations facing rising operational, regulatory and cyber risk. As connected devices become more embedded in sectors such as energy, utilities, manufacturing, healthcare and critical infrastructure, enterprises are under pressure to secure assets that are often distributed, long-lived and difficult to manage through traditional security tools.

The partnership addresses a practical challenge for customers: manual approaches to device identity, credential management and access control are increasingly difficult to scale. In large deployments, unmanaged or poorly governed devices can create visibility gaps, compliance issues and operational exposure. Device Authority’s KeyScaler platform is designed to automate identity lifecycle management for IoT and OT devices, from secure onboarding and credential provisioning through to certificate rotation, decommissioning and policy-driven access control.

Xalient’s role adds an important route-to-market dimension. By delivering the joint capability through its managed “as-a-service” security model, Xalient can support customers that want to improve IoT and OT security without adding complexity to internal teams.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

CAR-T therapy brings new approach to multiple myeloma treatment

CAR-T therapy is being used in multiple myeloma and is being studied earlier in the treatment pathway, with research focused on improving durability, safety and access.

Tern cuts H1 loss by 60% as portfolio growth and funding strengthen

Tern reduced its first-half loss by 60%, with net asset value improving and further fundraising strengthening the balance sheet. Additional funding has supported Talking Medicines and Device Authority, while continued progress across the portfolio provides further scope for value creation.

AI control of machines creates a new market for device trust

AI is beginning to control physical machines, increasing demand for technology that can verify device identity before those machines are allowed to act.

Peptide drug development expands beyond GLP-1

GLP-1 success is widening interest in peptide drug development, with the next phase focused on proving clinical value across new therapeutic areas.

Tern Plc announces 90% take-up of Open Offer

Tern Plc has received valid acceptances for 50.9 million Open Offer Shares, representing approximately 90% of the shares available. The fully underwritten offer will raise approximately £509,368 before expenses, with admission of the new shares expected on 24 September 2026.

Talking Medicines moves to capture pharma demand for better patient intelligence

Tighter US pharma advertising rules could increase demand for patient intelligence, supporting the relevance of Talking Medicines’ DrugVoice platform.

Search